IP Library Granted Patent US 6,852,793
Granted Patent B2
US 6,852,793 · App. 10/175,715 · Granted Feb 8, 2005

Low water content, high refractive index, flexible, polymeric compositions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,852,793
App. No.
10/175,715
Granted
Feb 8, 2005
Kind
B2
Abstract

Optically transparent, relatively high refractive index polymeric compositions and ophthalmic devices such as intraocular lenses and corneal inlays made therefrom are described herein. The preferred polymeric compositions are produced through the polymerization of one or more copolymers with one or more hydrophilic monomers and optionally one or more aromatic-based monomers, hydrophobic monomers or a combination thereof.

Claims (44)

1. Polymeric compositions comprising:

one or more aromatic-based copolymers of two or more monomers at least one of which being aromatic, wherein said two or more monomers are selected from the group consisting of C 1-10 alkyl methacrylate, C 1-10 alkyl acrylate, C 6-40 arylalkyl acrylate and C 6-40 arylalkyl methacrylate polymerized with one or more hydrophilic monomers selected from the group consisting of N,N-dimethylacrylamide, glycerol methacrylate and N-vinylpyrrolidinone and optionally with one or more monomers selected from the group consisting of aromatic-based monomers and hydrophobic monomers, to have a water content greater than 4.5 percent by weight but less than 15 percent by weight, a refractive index of approximately 1.45 or greater and a elongation of approximately 80 percent or greater.

2. Polymeric compositions comprising:

one or more aromatic-based copolymers of two or more monomers at least one of which being aromatic, wherein said two or more monomers are selected from the group consisting of C 1-10 alkyl methacrylate, C 1-10 alkyl acrylate, C 6-40 arylalkyl acrylate and C 6-40 arylalkyl methacrylate polymerized with one or more hydrophilic monomers selected from the group consisting of N,N-dimethylacrylamide, glycerol methacrylate and N-vinylpyrrolidinone and one or more aromatic-based monomers to have a water content greater than 4.5 percent by weight but less than 15 percent by weight, a refractive index of approximately 1.45 or greater and a elongation of approximately 80 percent or greater.

3. Polymeric compositions comprising:

one or more aromatic-based copolymers of two or more monomers at least one of which being aromatic, wherein said two or more monomers are selected from the group consisting of C 1-10 alkyl methacrylate, C 1-10 alkyl acrylate, C 6-40 arylalkyl acrylate and C 6-40 arylalkyl methacrylate polymerized with one or more hydrophilic monomers selected from the group consisting of N,N-dimethylacrylamide, glycerol methacrylate and N-vinylpyrrolidinone and one or more hydrophobic monomers to have a water content greater than 4.5 percent by weight but less than 15 percent by weight, a refractive index of approximately 1.45 or greater and a elongation of approximately 80 percent or greater.

4. The polymeric compositions of claim 1 or 2 wherein said aromatic-based monomers are selected from the group consisting of 3,3-diphenylpropyl methacrylate, 2-phenyloxyethyl methacrylate, 3-methacryloyloxypropyldiphenylmethylsilane, 2-(1-naphthylethyl) methacrylate, 3-phenylpropyl acrylate and 2-(2-naphthylethyl) methacrylate.

5. The polymeric compositions of claim 1 or 3 wherein said hydrophobic monomers are selected from the group consisting of 2-ethylhexyl methacrylate and methyl methacrylate.

6. A method of producing the polymeric compositions of claim 1 comprising:

producing one or more aromatic-based copolymers of two or more monomers at least one of which being aromatic, wherein said two or more monomers are selected from the group consisting of C 1-10 alkyl methacrylate, C 1-10 alkyl acrylate, C 6-40 arylalkyl acrylate and C 6-40 arylalkyl methacrylate, one or more hydrophilic monomers selected from the group consisting of N,N-dimethylacrylamide, glycerol methacrylate and N-vinylpyrrolidinone and optionally one or more monomers selected from the group consisting of aromatic-based monomers and hydrophobic monomers, to have a water content greater than 4.5 percent by weight but less than 15 percent by weight, a refractive index of approximately 1.45 or greater and a elongation of approximately 80 percent or greater.

7. A method of producing the polymeric compositions of claim 2 comprising:

producing one or more aromatic-based copolymers of two or more monomers at least one of which being aromatic, wherein said two or more monomers are selected from the group consisting of C 1-10 alkyl methacrylate, C 1-10 alkyl acrylate, C 6-40 arylalkyl acrylate and C 6-40 arylalkyl methacrylate, one or more hydrophilic monomers selected from the group consisting of N,N-dimethylacrylamide, glycerol methacrylate and N-vinylpyrrolidinone and one or more aromatic-based monomers to have a water content greater than 4.5 percent by weight but less than 15 percent by weight, a refractive index of approximately 1.45 or greater and a elongation of approximately 80 percent or greater.

8. A method of producing the polymeric compositions of claim 3 comprising:

producing one or more aromatic-based copolymers of two or more monomers at least one of which being aromatic, wherein said two or more monomers are selected from the group consisting of C 1-10 alkyl methacrylate, C 1-10 alkyl acrylate, C 6-40 arylalkyl acrylate and C 6-40 arylalkyl methacrylate, one or more hydrophilic monomers selected from the group consisting of N,N-dimethylacrylamide, glycerol methacrylate and N-vinylpyrrolidinone and one or more hydrophobic monomers to have a water content greater than 4.5 percent by weight but less than 15 percent by weight, a refractive index of approximately 1.45 or greater and a elongation of approximately 80 percent or greater.

9. The method of claim 6 or 7 wherein said aromatic-based monomers are selected from the group consisting of 3,3-diphenylpropyl methacrylate, 2-phenyloxyethyl methacrylate, 3-methacryloyloxypropyldiphenylmethylsilane, 2-(1-naphthylethyl) methacrylate, 3-phenylpropyl acrylate and 2-(2-naphthylethyl) methacrylate.

10. The method of claim 6 or 8 wherein said hydrophobic monomers are selected from the group consisting of 2-ethylhexyl methacrylate and methyl methacrylate.

11. A method of producing ophthalmic devices from the polymeric compositions of claim 1 , 2 or 3 comprising:

casting one or more polymeric compositions in the form of a rod;

lathing or machining said rod into disks; and

lathing or machining said disks into ophthalmic devices.

12. A method of producing ophthalmic devices from the polymeric compositions of claim 1 , 2 or 3 comprising:

pouring one or more polymeric compositions into a mold prior to curing;

curing said one or more polymeric compositions; and

removing said one or more polymeric compositions form said mold following curing thereof.

13. A method of using ophthalmic devices produced through the method of claim 11 comprising:

implanting said ophthalmic device within the eye.

14. The method of claim 11 wherein said ophthalmic device is an intraocular lens.

15. The method of claim 11 wherein said ophthalmic device is a corneal inlay.

16. The polymeric compositions of claim 1 , 2 or 3 wherein one or more strengthening agents are added prior to polymerization.

17. The polymeric compositions of claim 16 wherein said one or more strengthening agents are selected from the group consisting of cycloalkyl acrylates and methacrylates.

18. The polymeric compositions of claim 1 , 2 or 3 wherein one or more crosslinking agents are added prior to polymerization.

19. The polymeric compositions of claim 18 wherein said one or more crosslinking agents are selected from the group consisting of diacrylates and dimethacrylates of triethylene glycol, butylene glycol, neopentyl glycol, hexane-1,6-diol, thio-diethylene glycol and ethylene glycol, trimethylolpropane triacrylate, N,N′-dihydroxyethylene bisacrylamide, diallyl phthalate, triallyl cyanurate, divinylbenzene; ethylene glycol divinyl ether, N,N-methylene-bis-(meth)acrylamide, sulfonated divinylbenzene and divinylsulfone.

20. The polymeric compositions of claim 1 , 2 or 3 wherein one or more ultraviolet light absorbers are added prior to polymerization.

21. The polymeric compositions of claim 20 wherein said one or more ultraviolet light absorbers are selected from the group consisting of β-(4-benzotriazoyl-3-hydroxyphenoxy)ethyl acrylate, 4-(2-acryloxyethoxy)-2-hydroxybenzophenone, 4-methacryloyloxy-2-hydroxybenzophenone, 2-(2′-methacryloyloxy-5′-methylphenyl)benzotriazole, 2-(2′-hydroxy-5′-methacryoxyethylphenyl)-2H-benzotriazole, 2-[3′-tert-butyl-2′-hydroxy-5′-(3″-methacryloyloxypropyl)phenyl]-5-chlorobenzotriazole, 2-(3′-tert-butyl-5′-(3″-dimethylvinylsilylpropoxy)-2′-hydroxyphenyl]-5-methoxybenzotriazole, 2-(3′-allyl-2′-hydroxy-5′-methylphenyl)benzotriazole, 2-[3′-tert-butyl-2′-hydroxy-5′-(3″-methacryloyloxypropoxy)phenyl]-5-methoxybenzotriazole, and 2-[3′-tert-butyl-2′-hydroxy-5′-(3″-methacyloyloxypropoxy)phenyl]-5-chlorobenzotriazole.

22. The polymeric compositions of claim 1 , 2 or 3 wherein one or more free radical thermal polymerization initiators are added prior to polymerization.

23. The polymeric compositions of claim 22 wherein said one or more free radical thermal polymerization initiators are selected from the group consisting of acetyl peroxide, lauroyl peroxide, decanoyl peroxide, stearoyl peroxide, benzoyl peroxide, tert-butyl peroxypivalate and peroxydicarbonate.

24. The polymeric compositions of claim 1 , 2 or 3 wherein one or more ultraviolet light initiators are added prior to polymerization.

25. The polymeric compositions of claim 24 wherein said one or more ultraviolet light initiators are selected from the group consisting of benzoin methyl ether and benzoin ethyl ether.

26. A method of using ophthalmic devices produced through the method of claim 12 comprising:

implanting said ophthalmic device within the eye.

27. The method of claim 12 wherein said ophthalmic device is an intraocular lens.

28. The method of claim 13 wherein said ophthalmic device is an intraocular lens.

29. The method of claim 12 wherein said ophthalmic device is a corneal inlay.

30. The method of claim 13 wherein said ophthalmic device is a corneal inlay.

Assignments (20)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
Reel/Frame 073654/0242 →
ASSIGNMENT OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (059913/0548) Recorded Aug 14, 2025
From: CITIBANK, N.A., AS RESIGNING AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT
Reel/Frame 072469/0091 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 043251/0932) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH
Reel/Frame 061872/0099 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 048556/0758) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH COMPANIES INC.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0484 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 056811/0814) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061872/0669 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 059121/0001) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061873/0001 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 031156/0508) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061778/0446 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 034749/0689) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; UNIVERSITY OF ROCHESTER
Reel/Frame 061778/0146 →
PATENT SECURITY AGREEMENT Recorded May 10, 2022
From: BAUSCH & LOMB INCORPORATED
To: CITIBANK, N.A. AS COLLATERAL AGENT
Reel/Frame 059913/0548 →
SECURITY AGREEMENT Recorded Feb 10, 2022
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 059121/0001 →
SECURITY INTEREST Recorded Jun 8, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 056811/0814 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Jul 19, 2017
From: BAUSCH & LOMB INCORPORATED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0932 →